EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat

Zhijun Xiang, Bingbin Zhang, Shuangyi Cao, Long Cao, Lingwen Li, Dehua Huang, Qian Li, Yuxiang Chen, Xuelian Gong, Xiaohong Zhang, Ruizhi Li, Jinmiao Wu und 6 weitere

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Zhijun Xiang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR Chin…. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Trinitrobenzenesulfonic Acid, Colitis, Th17 Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea Hydro and Nuclear Power Central Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple lines of evidence suggest that Retinoic Acid Related Orphan Nuclear Receptor gamma t (RORγt) is a potent therapeutic target for inflammatory bowel disease (IBD). However, systemic blockade of RORγt easily leads to thymic lymphoma and aberrant liver function. Therefore, the development of gut-limited RORγt antagonists may lead to the development of innovative IBD therapeutics that improve safety and retain effectiveness. We discovered SPH7854, a potent and selective RORγt antagonist. The effect of SPH7854 on the differentiation of T helper 1 (Th1)/Th17/regulatory T (Treg) cells was evaluated in mouse and human primary cells. SPH7854 (2-(4-(ethylsulfonyl)phenyl)-N- (6-(2-methyl-2-(pyridin-2-yl) propanoyl)pyridin-3-yl)acetamide) dose-dependently inhibited interleukin-17A (IL-17A) secretion from mouse CD4 + T cells and human peripheral blood mononuclear cells (PBMC). Additionally, SPH7854 strongly suppressed Th17 cell differentiation and considerably promoted Treg cell differentiation while slightly affected Th1 cell differentiation from mouse CD4 + T cells. The pharmacokinetic (PK) studies indicated that SPH7854 was restricted to the gut: the bioavailability and maximal plasma concentration of SPH7854 after oral administration (6 mg/kg) were 1.24 ± 0.33 % and 4.92 ± 11.81 nM, respectively, in rats. Strikingly, oral administration of SPH7854 (5 mg/kg and 15 mg/kg) twice daily significantly alleviated 2, 4, 6-trinitrobenzensulfonic acid (TNBS)-induced colitis in rats. SPH7854, especially at 15 mg/kg, significantly alleviated symptoms and improved macroscopic signs and microscopic structure in rat colitis, with decreased colonic mucosal levels of IL-17A, IL-6, tumor necrosis factor α (TNFα), monocyte chemoattractant protein-1 (MCP-1) and myeloperoxidase (MPO). These evidences indicated that blockade of RORγt activity via a gut-limited antagonist may be an effective and safe therapeutic strategy for IBD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 1, Group F, Member 3Trinitrobenzenesulfonic AcidColitisTh17 CellsAnimalsHumansMaleRatsMiceRats, Sprague-DawleyT-Lymphocytes, RegulatoryCell DifferentiationDisease Models, AnimalInterleukin-17AcetamidesCells, CulturedAnti-Inflammatory AgentsColonMice, Inbred C57BL

Stichwörter der Autor:innen

ColitisGut-limitedIBDRORγtTh17Treg

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Trinitrobenzenesulfonic AcidInterleukin-17AcetamidesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: xiangzj@sphchina.com.
  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: zhangbb@sphchina.com.
  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: caosy@sphchina.com.
  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: caolong@sphchina.com.
  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: lilw@sphchina.com.
  • Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China. Electronic address: huangdh@sphchina.com.

Förderung

  • Korea Hydro and Nuclear Power Central Research Institute

Zitieren

APA

Xiang, Z., Zhang, B., Cao, S., Cao, L., Li, L., Huang, D., Li, Q., Chen, Y., Gong, X., Zhang, X., Li, R., Wu, J., Peng, Y., Huo, G., Xu, L., Zhang, Z., Li, D., & Xia, G. (2024). SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112884

Vancouver

Xiang Z, Zhang B, Cao S, Cao L, Li L, Huang D, et al. SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112884

BibTeX
@article{Xiang2024,
  author = {Xiang, Zhijun and Zhang, Bingbin and Cao, Shuangyi and Cao, Long and Li, Lingwen and Huang, Dehua and Li, Qian and Chen, Yuxiang and Gong, Xuelian and Zhang, Xiaohong and Li, Ruizhi and Wu, Jinmiao and Peng, Yayuan and Huo, Guoyong and Xu, Lixia and Zhang, Zhihui and Li, Di and Xia, Guangxin},
  title = {SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112884}
}
Kostenlos starten →